

CURRICULUM VITAE

Name: Donald R. Lannin, M.D.

Appointment: Professor, Clinician-Educator Track
Department of Surgery, Section of Oncology
Department of Oncology

Term: On a continuing basis without term beginning July 1, 2002

School Assignment: School of Medicine

Born: February 18, 1948
Minneapolis, Minnesota

Education: B.A. Biology , Stanford University
Stanford, California
September 1966 – June 1970

Doctor of Medicine, University of Minnesota
Minneapolis, Minnesota
September 1970 – May 1974

Career: June 1974 – June 1975, Internship, General Surgery
University of Minnesota
Minneapolis, Minnesota

July 1975 – June 1982, Residency, General Surgery
University of Minnesota
Minneapolis, Minnesota

July 1977- June 1980, NIH National Research Service Fellowship
(This fellowship was conducted while at University of MN but
funded by NIH)

July 1982- June 1988, Assistant Professor, Surgery
East Carolina University
Greenville, North Carolina

July 1988- June 1993, Associate Professor, Surgery
East Carolina University
Greenville, North Carolina

July 1993 – June 2002, Professor, Surgery
East Carolina University
Greenville, North Carolina

July 2002 – present, Professor of Surgery
Yale University School of Medicine
New Haven, CT

July 2002 – September 2010, Executive Director, Yale Breast
Center

October 2010 – present, Director Emeritus, Yale Breast Center

Board Certification: American Board of Surgery #29280,1983. Recertified 1992, 2002, and 2013.

Professional Honors or Recognition: Alpha Omega Alpha
Who's Who in Science and Medicine
American College of Surgeons Young Surgeon

Award

American Cancer Society Sword of Hope Award
ECU Family Practice Residency Teaching Award
Best Doctors in America (2006-2008)

Grant History:

- 1.Principal Investigator, "NSABP STAR Trial". 1999 - 2005
- 2.Co-Investigator, "Breast Cancer Screening in Eastern North Carolina". 7/87 - 6/91. NIH \$1,000,000 funded, in collaboration with UNC - School of Public Health.
- 3.Principal Investigator, "Psychosocial Factors Delaying Breast Cancer Presentation". American Cancer Society, \$240,130. 7/88 - 6/91 .
- 4.Principal Investigator, "Psychosocial Factors Delaying Breast Cancer Presentation". American Cancer Society, \$168,000. 7/91 - 6/93.
- 5.Co-Investigator, "Carolina Breast Cancer Study". NCI. Beth Newman, P.I. 5/1/93 - 4/30/98.
- 6.Principal Investigator, NSABP Breast Cancer Prevention Trial". NSABP, \$138,500. 6/1/93 - 5/31/98.
- 7.Co-Investigator, "NC Breast Cancer Screening Project". NIH, \$1,786,488. Joanne Earp, P.I. 1993-1999.
- 8.Principal Investigator, ECU Subcontract. "Managing Uncertainty to Promote Self Help in Breast Cancer". 1993-1997. \$143,000. Merle Mishel, Principal Investigator.
- 9.Principal Investigator, "Culturally Based Intervention for Breast Cancer in Rural African Americans". U.S. Army Medical Research Acquisition Activity, \$909,637.00. 9/30/96 - 12/31/01.
- 10.Principal Investigator, "Molecular Definition of DCIS that has become Invasive". Komen Society. \$1,465,856. 8/1/07 – 12/30/11.

Lectures:

- 1.The Effect of Cytomegalovirus Infection on the growth of murine fibrosarcomas. *Surgical Forum*. Chicago, Illinois. October 1979.
- 2.Two Distinct Types of Host Defense Mechanism against Murine Fibrosarcomas. American Association of Cancer Research. San Diego, Calif. May 1980.
- 3.The Effect of Cyclophosphamide in mice bearing Methylcholanthrene Induced Sarcomas. Society of University Surgeons Residents Meeting. Salt Lake City, Utah. February 1980.

4. The Thymus - Dependent Immune Response cannot mediate Immunosurveillance. *Surgical Forum*. Atlanta, Georgia. October 1980.
5. Local vs. Systemic Resistance to Tumors. The Association for Academic Surgery. Birmingham, Alabama. November 1980.
6. T cells must recognize Tumor Antigen in Association with Self-MHC Antigen. American Transplantation Society. Boston, Massachusetts. 1981.
7. Treatment of Experimental Liver Metastases with Localized Hyperthermia. Society of Surgical Oncology. (Ewing Society) New York, New York. May 1984.
8. Cost-Effectiveness of Fine Needle Biopsy of the Breast. Southern Surgical Association. Hot Springs, Virginia. December 1985.
9. Long Term Cure of Experimental Liver Tumors with Intraoperative Interstitial Hyperthermia. Association of Academic Surgery. Washington, D.C. November 1986.
10. A New Approach to Treatment of Liver Metastases. American Association of Cancer Research. Atlanta, Georgia. May 1987.
11. A Method to Selectively Localize Radioactive Protein Coated Beads within Tumors by Antibody Agglutination. Association of Academic Surgery. Salt Lake City, Utah. November 1988.
12. Difficulties in Diagnosis of Breast Cancer Before Age 50. American College of Surgeons, New Orleans, LA. October 1992.
13. Physical Exam for Breast Cancer Detection Is Less Sensitive for Women under 50. American Association of Cancer Research. San Francisco, CA. April 1994.
14. Influence of Patients' Confidant on Breast Cancer Presentation. NC. Cancer Research Symposium. Chapel Hill, February 1994.
15. Is the Hottest Node the Node Most Likely to be Positive in Lymphatic Mapping for Soft Tissue Tumors? American Society of Clinical Oncology. Los Angeles, CA. May 1998.
16. Prior Experience is the only Significant Factor Associated with Sentinel Node Mapping Failure in Breast Cancer. Society of Surgical Oncology. March 1999.
17. Facilitating Informed Screening Decisions: The Influence of Provider Discussions About Breast Cancer Risk and Screening Frequency. 24th Annual Meeting of the American Society of Preventive Oncology, Bethesda, Maryland. March 5-7, 2000.
18. The Need for Culturally Based Breast Cancer Education for Rural African American Women. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Atlanta, Georgia. June 8-12, 2000.
19. Comparison of Three Methods for Breast Lymphatic Mapping. Sentinel Node 2000, 2nd International Sentinel Node Congress. Santa Monica, California, December, 2000.
20. Preoperative Chemotherapy and Sentinel Node Biopsy for Breast Cancer. American Society of Breast Surgeons. Second Annual Meeting. La Jolla, California, May, 2001.
21. Comparison of Three Methods for Breast Lymphatic Mapping. Society of Surgical Oncology, Denver, Colorado, March 14-17, 2002.
22. Factors Contributing to a False Negative Sentinel Lymph Node Biopsy. American Society of Breast Surgeons, Boston, MA, April 24-28, 2002.
23. Impacting Cultural Attitudes in African-American Women to Decrease Breast Cancer Mortality. American Society of Breast Surgeons, Boston, MA, April 24-28, 2002.
24. Twenty-two year experience with recurring subareolar abscess / lactiferous duct fistula treated by a single breast surgeon. American Society of Breast Surgeons, Las Vegas, NV March 2004.
25. Gynecomastia. American Society of Breast Surgeons, Atlanta, GA, March 2005.

26. Should all breast cancers be diagnosed by needle biopsy? American Society of Breast Surgeons, Baltimore, MD, April 2006.
27. The influence of preoperative MRI in the timing and type of therapy in women newly diagnosed with breast cancer. *Am J Roentgenol* 2008; 190:A31-34.
28. The Yale-New Haven Breast Center: Lessons Learned from the first 1400 cancers. Yale Surgery Department Grand Rounds. Feb 11, 2009.
29. Surgical management of breast cancer. Yale Cancer Center Greek Week. July 6, 2009.
30. What is the role of nipple sparing mastectomy? New England Surgical Society. September 2009.
31. Yale Cancer Center Oncology Series on Breast Cancer. Surgical aspects of neoadjuvant chemotherapy. December 15, 2010.
32. Surgical and Oncologic Outcomes in Breast cancer patients undergoing Tattooing prior to Neoadjuvant Chemotherapy. ASCO Breast Cancer. San Francisco, CA. September 8, 2011.
33. How generalizable is the patient population enrolled in ACOSOG Z11? San Antonio Breast Conference. San Antonio, TX. December 8, 2011.
34. Validation of the Louisville Breast Sentinel Node Prediction Models and a Proposed Modification to Guide Management of the Node Positive Axilla. Southeastern Surgical Congress. Birmingham, Alabama. Feb 14, 2012.
35. The Myth of early detection of breast cancer. Yale Surgery Department Grand Rounds. Feb 15, 2012.
36. The Myth of early detection of breast cancer. *Best Practices in Breast Cancer Care*, Mindstream Education Event, Boston, Massachusetts. April 4-5, 2013.
37. Management of Lymph Nodes with Neoadjuvant Chemotherapy. Breast Clinical Series, February 5, 2013.

Undergraduate Teaching Activities:

- 1.M1 Anatomy lectures
- 2.M3 Surgical clerkship - Instructor
- 3.M4 Surgery selective - Instructor
- 4.Preceptor for several independent student research projects which were presented at the annual "ECU Medical Student Research Day". November 1986, 1988, 1989, 1992, and 1999.

Professional Service:

Study Sections

- 1.Department of Defense Breast Cancer Research Program (1997-1999)
- 2.NIH Subcommittee H to review ACOSOG trial group (2007, 2010)

Editorial Boards

- 1.Editor for Current Surgery, Surgical Oncology section
- 2.Editor, Annals of Surgical Oncology, Breast Section

ECU Committees

- 1.University Policy and Review Committee on Human Research (1982 -1995)
- 2."AIDS" Committee (1985 - 1991)
- 3.Promotion and Tenure Committee (1991-1992)
- 4.Leo W. Jenkins Cancer Center Executive Committee (1989-2001)
- 5.Compliance Committee (1998-2002)

6. Faculty Senate (1998-2001)

PCMH Committees

1. Clinical Procedures Review Committee (1984 - 1988)
2. AIDS Care Committee (1986 - 1990)
3. Cancer Committee (1985 - 2002)
4. Nutrition Committee (1985 - 86)

State and National Committees

1. American Cancer Society, North Carolina Division; Medical and Scientific Committee (1984 - 1995)
2. American Cancer Society, North Carolina Division; Board of Directors (1984 - 2002)
3. American Cancer Society, Member of National Assembly (1997 - 2002)
4. American College of Surgeons, North Carolina Cancer Committee (1985 - 2002)
5. North Carolina Comprehensive Breast and Cervical Cancer Control Committee (1993 - 2002)

Administrative Activities

1. Chief of Surgical Oncology (1982 - 2002)
2. Director, ECU Breast Clinic (1985 -2002)
3. Field Liaison Officer representing ECU/PCMH to the Commission on Cancer, American College of Surgeons (1986 - 2002)
4. Director, Leo W. Jenkins Cancer Center (1992-2001)
5. Executive Director, Yale-New Haven Breast Center (2002-2011)
6. Field Liaison Officer representing YNH to the Commission on Cancer, American College of Surgeons (2003 - 2011)

Yale University Committees

1. Steering Committee-The Breast Center-Smilow Cancer Hospital at Yale New Haven (2010-present)
2. Appointments and Promotions Committee, Yale Department of Surgery (2008-present)
3. Breast Fellowship Interview and Selection Committee, Yale University (2007-present)
4. Yale Cancer Center Committee (2003-present)
5. Surgical Intern Interview and Selection Committee, Yale Department of Surgery (2002-present)

Bibliography:

Peer-reviewed Original Research

1. Weissman I, **Lannin D**, Jerabek L, and Barclay T: Cellular immunity to heterologous erythrocytes in vitro. 1. The role of surface- adherent cells and specific mediators in an effector mechanism. *Cellular Immunology* 7:222-236, 1973.

2. Hayami M, Hellstrom I, Hellstrom KE and **Lannin DR**: Further studies of the ability of regressor sera to block cell-mediated destruction of Rous sarcomas. *Int. J. Cancer* 13:43-53, 1974.
3. **Lannin DR**, Howard R, Yu S, Collins ALT and McKhann CF: The effect of cytomegalovirus infection on the growth of murine fibrosarcomas -evidence for two separate host defense mechanisms against tumors. *Surgical Forum* 30:145-147, 1979.
4. **Lannin DR**, Yu S and McKhann CF: The thymus-dependent immune response cannot mediate immunosurveillance. *Surgical Forum* 31:400-402, 1980.
5. **Lannin DR**, Yu S, and McKhann CF: T cells must recognize tumor antigen in association with self-MHC antigen. *Transplantation Proceedings* 13(1):739-741, 1981.
6. Yu S, **Lannin DR**, Tsu-Collins, A.L., and McKhann, C.F.: Effect of cyclophosphamide on mice bearing methylcholanthrene-induced fibrosarcomas. *Cancer Research* 40:2756-2761, 1980.
7. **Lannin DR.**, Yu S, and McKhann CF: H-2 restriction of the T-cell response to chemically induced tumors: Evidence from FI - parent chimeras. *J. Immunology* 128(1): 263-268, 1982.
8. **Lannin DR**, Yu S, and McKhann CF: The thymus dependent response: Too little and too late for immunosurveillance. *Transplantation* 33(1):99- 100, 1982.
9. Thomas J, Merck T, Bray J, Smith M, **Lannin DR**, Pories WJ, and Thomas F: Synergistic Actions of Selenium and Polyclonal Immunoactivators. *Surgical Forum* 36:430-432, 1985.
10. **Lannin DR**, Silverman JF, Walker C, and Pories WJ.: Cost Effectiveness of Fine Needle Biopsy of the Breast. *Annals of Surgery* 203:474-480, 1986.
11. Silverman JF, **Lannin DR**, Meelheim D, and Pories WJ.: Subareolar Abscess of the Breast: The Role of Fine Needle Aspiration Biopsy in Diagnosis and Management. *Contemporary Surgery* 28:45-48, 1986.
12. Silverman JF, **Lannin DR**, Unverferth M, and Norris TH: Fine Needle Aspiration Cytology of Subareolar Abscess of the Breast: Spectrum of Cytomorphologic findings and potential diagnostic pitfalls. *Acta Cytologica* 30:413-419, 1986.
13. **Lannin DR**: Length of Hospital Stay for Routine Surgery. *Arch Surg* 122:120-121, 1987.
14. **Lannin DR**: Follow-Up of the Breast Cancer Patient. *North Carolina Medical Journal* 48(10):547-548, 1987.
15. Silverman JF, **Lannin DR**, O'Brien K, Norris T: The Triage Role of Fine Needle Aspiration Biopsy of Palpable Breast Masses: Diagnostic Accuracy and Cost Effectiveness. *Acta Cytol* 31:731-736, 1987.
16. Flickinger EG, Stanforth CA, Sinar DR, MacDonald KG, **Lannin DR**, and Gibson JH: Intraoperative Video Panendoscopy for Diagnosing Sites of Chronic Intestinal Bleeding. *American Journal of Surgery* 157:137-144, 1989.
17. Silverman JF, **Lannin DR**, Larkin EW, Feldman P, Frable W: Fine Needle Aspiration Cytology of Postirradiation Sarcomas, Including Angiosarcoma, With Immunocytochemical Confirmation. *Diagnostic Cytopathology* 5(3) :275-281, 1989.

18. Finley JF, Silverman JF, and **Lannin DR**: Fine Needle Aspiration Cytology of Breast Masses in Pregnant and Lactating Women. *Diagnostic Cytopathology* 53:255-259, 1989.
19. DeMasi RJ. and **Lannin DR**: Meleney's Synergistic Gangrene. *Infections in Surgery* 9(9): 38-40, 1990.
20. Harris RP, Fletcher SE, Gonzalez JJ, **Lannin DR**, Degnan D, Earp JA, Clark R: Mammography and Age: Are We Targeting the Wrong Women? *Cancer* 67:2010-2014, 1991.
21. **Lannin DR**: Preoperative Chemotherapy for Breast Cancer. *Current Surgery* 48(3): 132-135, 1991.
22. Fletcher SW, Harris RP, Gonzalez JJ, Degnan D, **Lannin DR**, Strecher, Victor J., Pilgrim, Carol, Quade, Dana, Earp, JoAnne, and Clark, Richard L.: Increasing Mammography Utilization Among Older Women: A Controlled Study. *JNCI* 85:112-120, January 1993.
23. **Lannin DR**, Harris RP, Swanson FH, Edwards MS, Swanson MS, and Pories WJ: Difficulties in Diagnosis of Breast Cancer before Age 50. *Surgery Gynecology and Obstetrics*, 177:457-462, November 1993.
24. Mathews HF, **Lannin DR**, and Mitchell JP: Coming to Terms with Advanced Breast Cancer: Black Women's Narratives from Eastern North Carolina. *Journal of Social Science and Medicine*, 38(6):789-800, 1994.
25. Royak-Schaler R, DeVellis BM, Sorenson JR, **Lannin DR**, Wilson KR, and Emerson JA. Breast Cancer in African American Families: Risk Perception, Cancer Worry and Screening Practices of First Degree Relatives. *Annals of the New York Academy of Sciences*. 768(9):281-285, 1995.
26. DeMasi RJ, **Lannin DR**. Isolated Splenic Metastasis from Colon Carcinoma: Successful Management with Splenectomy. *Surgical Rounds*. 19(12):559-561, 1996.
27. Thomas P, Raab M, **Lannin DR**, Slagel D, Silverman J. Racial Differences in Breast Cancer in a Rural Population: Comparison of Cytologic Nuclear Grade, Other Prognostic Factors, and Outcomes for Tumors Diagnosed by Fine-Needle Aspiration Biopsy. *The Breast Journal*. 4(2):104-111, 1998.
28. Silverman JF, Raso DS, Elsheikh TM, **Lannin DR**. Fine-Needle aspiration cytology of subareolar abscess of the male breast. *Diagn Cytopathol* Jun;18(6):441-4, 1998.
29. **Lannin DR**, Matthews HF, Mitchell J, Swanson M, Swanson F, Edwards M. The Influence of Race, Socioeconomic Factors, and Cultural Factors on Breast Cancer Stage in the Rural Southern United States. *Journal of the American Medical Association*. 279(22): 1801-1807, 1998.
30. Hrushesky WJM, **Lannin DR**, Haus E. Evidence for an Ontogenetic Basis for Circadian Coordination of Cancer Cell Proliferation. *Journal of the National Cancer Institute*. 90(19): 1480-1484, 1998.
31. Tafra L, Chua A, Ng P, Aycock D, Swanson M, **Lannin DR**. Filtered Versus Unfiltered Technetium Sulfur Colloid in Lymphatic Mapping: A Significant Variable in a Pig Model. *Annals of Surgical Oncology*, 6(1): 83-87, 1999.
32. Hrushesky WJM, Lester B, **Lannin DR**. Circadian Coordination of Cancer Growth and Metastatic Spread. *Int. J. Cancer*: 83, 365-373 (1999).

33. Pololi L, **Lannin DR**, Mathews H, Mitchell J, Swanson MS, Swanson FH. The Need for Culturally Based Breast Cancer Education for Women Living in North Carolina. *Medical Encounter: A Publication of the American Academy on Physician & Patient*. Vol. 15, No. 4. 10-11, Fall 2000.
34. Tafra L, **Lannin DR**, Swanson M, VanEyck JJ, Verbanac KM, Chua AN, Ng PC, Edwards MS, Halliday BE, Henry CA, Sommers LM, Carman CM, Molin MR, Yurko JE, Perry RR, Williams R. Multicenter Trial of Sentinel Node Biopsy for Breast Cancer Using Both Technetium Sulfur Colloid and Isosulfan Blue Dye. *Annals of Surgery*. Vol 233, No. 1, 51-59, 2001.
35. Kersey TW, VanEyck J, **Lannin DR**, Chua AN, Tafra L. Comparison of Intradermal and Subcutaneous Injections in Lymphatic Mapping. *Journal of Surgical Research*. 96(2): 255-9, 2001 Apr.
36. Tafra L, Verbanac KM, **Lannin DR**. Preoperative Chemotherapy and Sentinel Lymphadenectomy for Breast Cancer. *The American Journal of Surgery*. 182 (2001) 312-315.
37. Royak-Schaler R, Klabunde CN, Greene WF, **Lannin DR**, DeVellis B, Wilson KR, Chevront B. Communicating Breast Cancer Risk: Patient Perceptions of Provider Discussions. *Medscape Women's Health eJournal* 7(2), 2002.
38. **Lannin DR**, Mathews HF, Mitchell J, Swanson MS. Impacting cultural attitudes in African-American women to decrease breast cancer mortality. *The American Journal of Surgery*. 184 (2002) 418-423.
39. Mitchell J, **Lannin DR**, Mathews HF, Swanson MS. Religious beliefs and breast cancer screening. *Journal of Women's Health & Gender-Based Medicine*. 2002; 11(10):907-915.
40. **Lannin DR**, Haffty BG. End Results of Salvage Therapy after Failure of Breast-Conservation Surgery. *Oncology* 18(3) 272-279, 2004.
41. **Lannin DR** Twenty-two year experience with recurring subareolar abscess / lactiferous duct fistula treated by a single breast surgeon. *The American Journal of Surgery*. 188:407-410, 2004.
42. Ahn PH, Vu HT, **Lannin DR**, Obedian E, DiGiovanna MP, Burtness B, and Haffty BG. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. *Journal Clinical Oncology*. 23:17-23, 2005.
43. Alpert TE, Kuerer HM, Arthur DW, **Lannin DR**, Haffty BG. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for breast preservation. *Int J Radiat Oncol Biol Phys*. 63(3):845-51, 2005.
44. Kim JH, Bossuyt V, Ponn T, **Lannin DR**, Haffty BG. Cyclooxygenase-2 expression in postmastectomy chest wall relapse. *Clin Cancer Res*. 11(14):5199-205, 2005.
45. Haffty BG, Silber A, Matloff E, Chung J, and **Lannin DR**. Racial Differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of Early Onset Breast Cancer patients: African-American compared to White women. *Journal of Medical Genetics* 43(2): 133-137, 2006.

46. **Lannin DR**, Ponn T, Andrejeva L, and Philpotts L. Should all breast cancers be diagnosed by needle biopsy? *The American Journal of Surgery*. 192:450-454, 2006.
47. He Q, Hooley RJ, **Lannin DR**, Weinreb JC, Bossuyt VIJ. In vivo MR Spectroscopic Imaging of Polyunsaturated Fatty Acids (PUFA) for early intervention of Human Breast Cancer. *Magnetic Resonance in Medicine*, 58:1079-1085, 2007.
48. **Lannin DR**, Grube B, Black DS, Ponn T. Breast Tattoos for Planning Surgery following Neoadjuvant Chemotherapy. *The American Journal of Surgery* 194:518-520, 2007.
49. Grube B, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, DiGiovanna MP, Chung G, Abu-Khalaf MM, Miller KD, Higgins SA, Philpotts L, Tavassoli FA, **Lannin DR**. Breast Sentinel Lymph Node Dissection Before Preoperative Chemotherapy. *Arch Surg* 143(7): 692-700, 2008.
50. Wolff EF, Martel M, Gwin K, and **Lannin DR**. Case-Report: Synchronous primary breast and ovarian cancer with ovarian cancer metastases to a breast sentinel lymph node. *The Breast Journal* 15(2):203-205, 2009.
51. Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung G, DiGiovanna M, Miller K, Higgins S, Weidhaas J, Harris L, Tavassoli FA, **Lannin DR**. Preoperative Chemotherapy Decreases the need for Re-excision of Breast Cancers between 2 and 4 cm diameter. *Ann Surg Oncol* 16(3):697-702, 2009.
52. Schwartz JC, Rishi M, Christy CJ, Grube BJ, and **Lannin DR**. What do breast surgeons do? *The American Journal of Surgery* 198:544-546, 2009.
53. Broer N, Narayan D, **Lannin DR**, and Grube B. A novel technique for nipple-sparing mastectomy and immediate reconstruction in patients with macromastia. *Plast Reconstr Surg*. 126(2):89e-92e. 2010.
54. Li A, Liu Z, Lezon-Geyda K, Sarkar S, **Lannin DR**, Schulz V, Krop I, Winer E, Harris L, Tuck D. GPHMM: An integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays; *Nucleic Acids Res*. 39(12):4928-41, 2011.
55. Castrucci W, **Lannin D**, Haffty BG, Higgins SA, and Moran MS. Using Nodal Ratios to Predict Risk of Regional Recurrences in Patients treated with Breast Conservation Therapy with 4 or more Positive Lymph Nodes. *ISRN Surgery, Volume 2011, Article ID 874814, 5 pages*.
56. Parikh RR, Haffty BG, **Lannin DR**, and Moran MS. Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. *Int J Radiat Oncol Biol Phys*. 82(1):7-13, 2012.
57. Welsh A, **Lannin DR**, Young G, Sherman M, Figueroa J, Henry N, Ryden L, Kim C, Love R, Schiff R, and Rimm D. Cytoplasmic Estrogen Receptor in Breast Cancer. *Clin Cancer Res*. 18(1):118-26, 2012.

58. Bordeaux JM, Cheng H, Welsh AW, Haffty BG, **Lannin DR**, Wu X, Su N, Ma X-J, Luo Y, and Rimm DL. Quantitative *In Situ* Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen. *PLoS One*. 2012;7(5):e36559. doi: 0.1371/journal.pone.0036559. Epub 2012 May 11.
59. **Lannin DR**, Killelea B, Horowitz N, Chagpar AB. Validation of the Louisville Breast Sentinel Node Prediction Models and a Proposed Modification to Guide Management of the Node Positive Axilla. *Am Surg*. 78(7):761-5, 2012.
60. Killelea BK, **Lannin DR**, Horvath LJ, Horowitz NR, Chagpar AB. Factors Associated with Breast MRI Use: A population-based Analysis. *Ann Surg Oncol* 20(6):1798-1805, 2013.
61. Sue GR, **Lannin DR**, Killelea B, Tsangaris T, Chagpar AB. Does time to definitive treatment matter in patients with ductal carcinoma in situ? *Am Surg*. 79(6): 561-5, 2013.
62. Bai HX, Motwani SB, Higgins SA, Haffty BG, Wilson LD, **Lannin DR**, Evans SB, Moran MS. Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes? *Int J Clin Oncol*. 2013 Jun 19. [Epub ahead of print]
63. Sue GR, **Lannin DR**, Killelea B, Chagpar AB. Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. *Am J Surg*. 2013 Jun 18. doi:pii: S0002-9610(13)00288-2. 10.1016/j.amjsurg.2013.01.039. [Epub ahead of print]
64. Killelea BK, Grube BJ, Rishi M, Philpotts L, Tran EJ, **Lannin DR**. Is the use of preoperative breast MRI predictive of mastectomy? *World J Surg Onc* 2013, 11:154. DOI: 10.1186/1477-7819-11-154
65. Nicholson A, Bishop J, **Lannin DR**, Killelea BK, Guo X, Cha C, Dixon M. Triple-negative breast cancer: molecular characterization and targeted therapies. *Breast Cancer Manage*. 2(5): 417-430, 2013.
66. Killelea BK, Chagpar AB, Bishop J, Horowitz NR, Christy C, Tsangaris T, Raghu M, **Lannin DR**. Is there a correlation between breast cancer molecular subtype and mammographic appearance? *Ann Surg Oncol* (in press).
67. Wiznia LE, **Lannin DR**, Evans SB, Hofstatter EW, Horowitz NR, Killelea BK, Tsangaris TN, Chagpar AB. "The number of lymph nodes dissected in breast cancer patients matters.", *Annals of Surgical Oncology* (2013, in press).
68. Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea B, Knobf MT, **Lannin DR**, Abu-Khalaf M, Horowitz NR, Chagpar AB. "Is The Financial Burden of Cancer Impacting Survivors' Quality of Life?", *Journal of Clinical Oncology* (2013, submitted).

Editorials, Reviews, Chapters, Books

1. **Lannin DR** and McKhann CF: Current status of Carcinoembryonic Antigen (CEA) in gastrointestinal malignancy. *Gastrointestinal Surgery*, J.S. Najarian J.P. Delaney, Eds., *Symposia Specialists*, Miami, 1979.

2. **Lannin DR:** "Breast Cancer" in Guidelines for the Follow- Up of The Cancer Patient. Robert S. Sandler (ed) *The North Carolina Division of the American Cancer Society* 1987; pp.1-2.
3. **Lannin DR:** Surgical Pro's and Con's - Medical Malpractice. *Journal of American College of Surgeons*, 79:505-508, 1994.
4. **Lannin DR**, Scott-Conner CEH. Breast surgery, pp. 68-70. In: Cox SS, Pories WJ, Foil MB, Patselas TN, eds. *Surgical Resident Curriculum*, 2nd ed. The Association of Program Directors in Surgery, Arlington VA, 1995.
5. Kopelman LM, **Lannin DR**, and Kopelman AE: Preventing and Managing Unwarranted Biases Against Patients. *Surgical Ethics*. McCullough LM, Brody B, (ed.) Oxford University Press 1998; pp. 242-254.
6. Haffty BG, **Lannin DR**. Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option? *European Journal of Cancer* 40 (2004) 1105-1108.
7. **Lannin DR**. How many breast cancer cells in a sentinel lymph node are OK? *Annals of Surgical Oncology* 11(6): 553-554, 2004.
8. **Lannin DR** and Ponn T. What should we teach women about breast self-examination today? *Journal of Women's Health* 14(6): 505-506, 2005.
9. **Lannin DR**. Cystosarcoma Phyllodes. *Emedicine, Clinical Knowledge Base*. www.imecine.com, 2006
10. Tavasoli FA and **Lannin DR**. Precancerous lesions of the breast. *Nature Clinical Practice Oncology* (2009) 6, E1 doi:10.1038/nponc1344
11. Christy CJ, Grube BJ and **Lannin DR**. Reply to Preoperative Chemotherapy and Potential Impact on Re-excision for Early Breast Cancer. *Ann Surg Oncol* (2009) 16:2958-2959.
12. **Lannin DR** and Lockwood C. Appraising the benefit of breast cancer screening. *Contemporary Ob/Gyn (February 1, 2010)*
13. Sowden M, Grube B, Killelea B, and **Lannin DR**. Surgical Intervention following Neoadjuvant Chemotherapy in Breast Cancer. in *Neoadjuvant Chemotherapy: Current Applications in Clinical Practice*. Oliver Bathe, (Ed). pages 31-40. InTech publishing, 2012.
14. **Lannin DR**. Realistic appraisal of the benefits of mammography. *Arch. Int. Med* 172(8): 672-673, 2012.
15. **Lannin DR**. Effect of screening mammography on breast cancer incidence. *N Engl J Med* 368(7):678, 2013.